Tangeritin is one of the Citrus bioflavonoids and plays a role, like many flavonoids, in reducing the risk for certain cancers. Tangeritin has also shown promise in protecting nerve cells.

Sytrinol has polymethoxylated flavones (PMFs) that decrease apoprotein B, a structural protein needed for endogenous synthesis of LKL cholesterol. PMFs (tangeritin and nobiletin) decrease diacylglycerol acetyl transferase, a liver enzyme needed for endogenous synthesis of triblycerides. Sytrinol has been promoted for those with cholesterol issues.

Tangeritin and cancer
Treatment of metastatic melanoma B16F10 by the flavonoids tangerotin, rutin, and diosmin.
J Agric Food Chem. 2005. Pathology Department, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain.
Melanoma is one of the most frequently metastasizing malignant neoplasias. This study examines an experimental model of pulmonary metastasis and the B16F10 cell subline, highly metastatic in the lung. Antimetastatic effects of the flavonoids tangeritin, rutin, and diosmin were analyzed, and at the same time an analysis of the metastatic activity of ethanol was performed, considered to be necessary because it is used as a vehicle for administering the flavonoids. The greatest reduction in the number of metastatic nodules (52%) was obtained with diosmin. Rutin- and tangeritin treated groups also showed reductions of the same index compared with the ethanol group. It would seem that structural factors would better explain these results and the antimetastatic activity of each flavonoid and the respective metabolites.

Breast cancer suppression
Biochimie. 2013. Chemotherapeutic effect of tangeritin, a polymethoxylated flavone studied in 7, 12-dimethylbenz(a)anthracene induced mammary carcinoma in experimental rats. The results of the present study clearly indicate that it significantly suppresses DMBA induced breast cancer in rats.

Tangeritin Research
A safety study of oral tangeretin and xanthohumol administration to laboratory mice.
In Vivo. 2005.
The detection of molecular targets for flavonoids in cell signalling has opened new perspectives for their application in medicine. Both tangeretin, a citrus methoxyflavone, and xanthohumol, the main prenylated chalcone present in hops (Humulus lupulus L.), act on the mitogen-activated protein kinase pathway and await further investigation for administration in vivo. A safety study was designed in laboratory mice orally administered concentrates of purified tangeretin (1 x 10(-4) M) or xanthohumol (5 x 10(-4) M) at libitum for 4 weeks. Blood samples were collected for the analysis of a variety of haematological and biochemical parameters. A reduction of the circulating lymphocyte number was noticed for tangeretin, while all other parameters were unaffected by treatment with either tangeretin or xanthohumol. The parameters encompassed an integrity check of the following tissues and organs: bone marrow, liver, exocrine pancreas, kidneys, muscles, thyroid, ovaries and surrenal cortex. Furthermore, no differences were noted in the metabolism of proteins, lipids, carbohydrates and uric acid, as well as in ion concentrations. All data indicate that oral administration of tangeretin or xanthohumol to laboratory mice does not affect major organ functions and opens the gate for further safety studies in humans.

Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation.
FEBS Lett. 2005.
Tangeretin is a methoxyflavone from citrus fruits, which inhibits growth of human mammary cancer cells and cytolysis by natural killer cells. Attempting to unravel the flavonoid's action mechanism, we found that it inhibited extracellular-signal-regulated kinases 1/2 (ERK1/2) phosphorylation in a dose- and time-dependent way. In human T47D mammary cancer cells this inhibition was optimally observed after priming with estradiol. The spectrum of the intracellular signalling kinase inhibition was narrow and comparison of structural congeners showed that inhibition of ERK phosphorylation was not unique for tangeretin. Our data add tangeretin to the list of small kinase inhibitors with a restricted intracellular inhibition profile.

Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease.
Neuroreport. 2001.
Neuroprotective effects of a natural antioxidant tangeritin, a citrus flavonoid, were elucidated in the 6-hydroxydopamine (6-OHDA) lesion rat model of Parkinson's disease (PD), after bioavailability studies. Following the chronic oral administration (10 mg/kg/day for 28 days), significant levels of tangeritin were detected in the hypothalamus, striatum and hippocampus. These studies, for the first time, give evidence that tangeritin crosses the blood-brain barrier. The significant protection of striato-nigral integrity and functionality by tangeritin suggests its potential use as a neuroprotective agent.

Food Chem Toxicol. 2014. Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (Citri reticulatae pericarpium). Inhibiting microglial activation-mediated neuroinflammation has become a convincing target for the development of functional foods to treat neurodegenerative diseases. Tangerine peel (Citri reticulatae pericarpium) has potent anti-inflammatory capacity; however, its anti-neuroinflammatory capacity and the corresponding active compounds remain unclear. Overall, tangerine peel possesses potent anti-neuroinflammatory capacity, which is attributed to the collective effect of hesperidin, nobiletin, and tangeretin.